ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2022 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Experience of tocilizumab in hospital patients with moderate COVID-19
About authors
1 Peoples’ Friendship University of Russia, Moscow, Russia
2 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia
3 Clinical Hospital for Infectious Diseases №1, Moscow, Russia
4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Correspondence should be addressed: Olga A. Burgasova
Volokolamskoe sh., 47, str. 8, korp. 5, Moscow, 125310, Russia; ur.liam@avosagrubaglo
About paper
Author contribution: OA Burgasova — initiative and design, supervision of the clinical part of the study, writing of the manuscript; SV Dolinniy — literature review, clinical observations, data processing; VB Tetova — literature review, editing of the manuscript; DA Ogarkova — statistical analysis; MA Odnoralov, VV Baсalin — clinical observations, processing of clinical and laboratory data; SV Smetanina — concept; NA Antipyat — supervision of the clinical part of the study, MV Taranova — literature review, data processing.
Compliance with ethical standards: the study was approved by the ethics committee at the Clinical Hospital for Infectious Diseases №1 (Protocol 1 of January 11, 2021); all participants provided informed consent for the study.
Received: 2022-03-10
Accepted: 2022-04-03
Published online: 2022-04-15
|
Table 1. Structure of clinical symptoms in patients receiving tocilizumab vs. standard therapy (+dexamethasone)
Table 2. Baseline data, dynamics of clinical and laboratory parameters, and clinical outcomes in patients receiving tocilizumab vs. standard therapy (+dexamethasone)
Table 3. Dynamics of clinical and laboratory parameters in patients treated with tocilizumab
Table 4. Dynamics of clinical and laboratory parameters in patients treated with standard therapy (+dexamethasone)
